Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study
- John R. Zalcberg
- , Michael C. Heinrich
- , Suzanne George
- , Sebastian Bauer
- , Patrick Schöffski
- , César Serrano
- , Hans Gelderblom
- , Robin L. Jones
- , Steven Attia
- , Gina D'Amato
- , Ping Chi
- , Peter Reichardt
- , Neeta Somaiah
- , Julie Meade
- , Vienna Reichert
- , Kelvin Shi
- , Matthew L. Sherman
- , Rodrigo Ruiz-Soto
- , Margaret von Mehren
- , Jean Yves Blay
- Monash University
- Alfred Health
- Oregon Health and Science University
- Dana-Farber Cancer Institute
- University of Duisburg-Essen
- KU Leuven
- Vall d'Hebron Institute of Oncology
- Leiden University
- Royal Marsden Hospital
- Mayo Clinic Florida
- University of Miami
- Memorial Sloan-Kettering Cancer Center
- Fresenius AG
- University of Texas MD Anderson Cancer Center
- Centre Léon Bérard
- Deciphera Pharmaceuticals, LLC.
Research output: Contribution to journal › Article › peer-review
35
Scopus
citations